Novartis AG

OTC: NVSEF · Real-Time Price · USD
120.78
5.28 (4.57%)
At close: Aug 15, 2025, 11:40 AM

Novartis Balance Sheet Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
11.46B 13.39B 7.52B 12.41B
Short-Term Investments
1.89B 680M 11.41B 15.92B
Long-Term Investments
1.13B 1.83B 2.55B 3.24B
Other Long-Term Assets
4.53B 11.82B 1.11B 2.21B
Receivables
9.54B 8.12B 8.94B 8.82B
Inventory
5.71B 5.91B 7.17B 6.67B
Other Current Assets
118.28M 1.25B 2.03B 1.72B
Total Current Assets
29.7B 30.48B 36.91B 45.72B
Property-Plant & Equipment
10.85B 10.92B 12.2B 13.11B
Goodwill & Intangibles
51.67B 44.89B 60.95B 63.78B
Total Long-Term Assets
72.54B 69.46B 80.54B 86.08B
Total Assets
102.25B 99.94B 117.45B 131.79B
Account Payables
4.57B 4.93B 5.15B 5.55B
Deferred Revenue
127M 98M 123M 123M
Short-Term Debt
8.09B 6.08B 5.93B 6.29B
Other Current Liabilities
10.4B 9.88B 11.94B 12.94B
Total Current Liabilities
28.69B 26.39B 28.66B 30.21B
Long-Term Debt
21.37B 18.44B 20.24B 22.9B
Other Long-Term Liabilities
4.08B 4.52B 4.91B 4.54B
Total Long-Term Liabilities
29.43B 26.8B 29.37B 33.77B
Total Liabilities
58.12B 53.2B 58.03B 63.97B
Total Debt
31.26B 26.35B 27.96B 31.09B
Common Stock
791.3M 825M 890M 901M
Retained Earnings
46.46B 49.63B 63.57B 70.9B
Comprehensive Income
-3.25B -3.76B 58.54B 66.8B
Shareholders Equity
44.05B 46.67B 59.34B 67.66B
Total Investments
3.02B 2.4B 13.97B 19.16B